Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06801591 + PF-08046037 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06801591 | PF06801591|PF 06801591|Sasanlimab | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983). | |
| PF-08046037 | PF08046037|PF 08046037 | PF-08046037 (SGN-PDL1iT) is an immune-stimulating antibody conjugate comprising an antibody targeting CD274 (PD-L1) linked to a TLR7 agonist, which potentially induces antitumor immune activity (Cancer Res (2025) 85 (8_Supplement_1): 5840). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06974734 | Phase I | PF-08046037 PF-06801591 + PF-08046037 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | Recruiting | USA | 1 |